期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

美罗华的临床应用进展 被引量：8

Progress on clinical application of rituximab
下载PDF
导出
摘要 美罗华是一种抗CD20单克隆抗体,可特异地与B淋巴细胞表面的CD20抗原结合,可治疗B细胞相关的疾病。目前美罗华的临床应用越来越广泛,取得了良好的临床效果。该文就其缶床应用进展作一简单综述。 Rituximab is a kind of anti CD20 monoclonal antibody which can specifically bind with CD20 anti- gen on B lymphocyte surface. It can be used for the treatment of B cell associated diseases. At present the clinical ap- plication of rituximab is more and more extensive. It achieved good clinical results. This article will briefly reviews its clinical application.
作者 黄晓春 谭毅
机构地区 桂林市人民医院血液科
出处 《中国临床新医学》 2012年第7期659-663,共5页 CHINESE JOURNAL OF NEW CLINICAL MEDICINE
关键词 美罗华 治疗 CD20 Rituximab Therapy CD20
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献28

  • 1Johnson P,Glennie M.The mechanisms of action of rituximab in the elimination of tumor cells[J].Semin Oncol,2003,30(1 Suppl 2):3-8.
  • 2Ghetie MA,Bright H,Vitetta ES.Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin[J].Blood,2001,97(5):1392-1398.
  • 3Pfreundschuh M,Kuhnt E,Trümper L,et al.CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma:6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group[J].Lancet Oncol,2011,12(11):1013-1022.
  • 4Fowler N,Kahl BS,Lee P,et al.Bortezomib,bendamustine,and rituximab in patients with relapsed or refractory follicular lymphoma:the phase II VERTICAL study[J].J Clin Oncol,2011,29(25):3389-3395.
  • 5Tobinai K,Igarashi T,Itoh K,et al.Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab:a multicenter phase II study[J].Cancer Sci,2011,102(9):1698-1705.
  • 6Byrd JC,Rai K,Peterson BL,et al.Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia:an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011[J].Blood,2005,105(1):49-53.
  • 7张丽,向兵,王双,李颖,刘玉霞.一例难治性慢性淋巴细胞白血病患者的循证治疗[J].中国循证医学杂志,2011,11(4):464-467. 被引量：1
  • 8Robak T,Dmoszynska A,Solal-Céligny P,et al.Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia[J].J Clin Oncol,2010,28(10):1756-1765.
  • 9Zaja F,Vianelli N,Volpetti S,et al.Low-dose rituximab in adult patients with primary immune thrombocytopenia[J].Eur J Haematol,2010,85(4):329-334.
  • 10Pasa S,Altintas A,Cil T,et al.The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura[J].J Thromb Thrombolysis,2009,27(3):329-333.

二级参考文献15

  • 1Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes [J]. Immunol Today,1994,15(9):450-454.
  • 2Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximba in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma [J]. J Clin Oncol,2001,19(2):389-397.
  • 3Sivaraman S, Venugopal P, Ranganathan R, et al. Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia [J]. Cytokines Cell Mol Ther,2000,6( 2) :81-87.
  • 4Rhodes EG, Olive C, Flynu MP.A serum-free culture method for myeloma progenitors in vitro:proliferative and immunophenotypic characteristics [J]. Exp Hematol, 1990,18:79-83.
  • 5Brich JR, Boraston RC, Metcalfe H, et al. Selecting and designing cell lines for improved physiological characteristics [J]. Cytotechnology,1994,15(1-3):11-16.
  • 6Bensinger WI, Buckner D, Gahrton G. Allogeneic stem cell transplantation for multiple myeloma [J]. Hematol Oncol Clin Nor Am,1997,11:147-157.
  • 7Kneller A, Raanani P, Hardan I, et al. Therapy with thalidomide in refractory multiple myeloma patients-the revival of an old drug [J]. Br J Haemtol,2000,108:391-393.
  • 8Goldmacher VS,Bourret LA,Levine BA, et al.Anti-CD38-blocked ricin:an immunotoxin for the treatment of multiple myeloma [J]. Blood,1994,84(9):3017-3025.
  • 9Treon SP,Shima Y,Grossbard ML,et al.Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens [J]. Ann Oncol,2000,11(suppl.1):107-111.
  • 10Singhal S,Mehta J,Desikan R,et al. Antitumor activity of thalidomide in refractory multiple myeloma [J].N Eng J Med, 1999,341(21):1565-1571.

共引文献3

同被引文献53

  • 1刘光陵,茅松,夏正坤,樊忠民,任献国,何旭,孙涛,高远赋.利妥昔单抗治疗患儿激素依赖型肾病的初步研究[J].医学研究生学报,2011,24(5):482-484. 被引量：7
  • 2王海燕.肾脏病学[M].3版.北京:人民卫生出版社,2008:8262.
  • 3孙传兴.临床疾病诊断依据治愈好转标准[M].北京：人民军医出版社,1998.395.
  • 4古爱虎,寇克韧,王勇,等.非霍奇金淋巴瘤患者血清LDH与B2-MG检测及其临床意义[J].中国临床新医学,2012,5(7):659-663.
  • 5Cheson BD, Homing SJ, Coiffier B,et al.Report of an in- ternational workshop to standardize response criteria for non-Hodgkin's lymphomas [ J].J Clin Oncol, 1999, 17 (4) : 1244-1253.
  • 6Pasqualucci L,Dalla-Favera R.The Genetic Landscape of Diffuse Large B-Cell Lymphoma [ J ]. Semin Hematol, 2015,52(2) :67-76.
  • 7Ha H, Keam B, Kim TM, et al. Reduced dose intensities of doxorubicin in elderly patients with DLBCL in rituximab era [ J ]. Cancer Res Treat, 2015, 10 ( 41 ) : 339-342.
  • 8Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, et al. Regu- lation of CD20 in rituximab-resistant cell lines and b-cell non-hodgkin tymphoma [ J ]. Clin Cancer Res, 2012, 18 (4) : 1039-1050.
  • 9Ulrich W, Riccardo AA. Diffuse large B-cell Non- Hodgkin' s lymphoma (DLBCL-NHL) [ M ]. London : Springer, 2015 : 185 -202.
  • 10Molina A.A deeade of rituximab: improving survival out- comes in non-Hodgkin' s lymphoma[ J ].Annu Rev M ed, 2008,59(12) :237-250.

引证文献8

二级引证文献42

中国临床新医学
2012年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部